MX2008012053A - Promotores de apoptosis de molecula pequeña. - Google Patents
Promotores de apoptosis de molecula pequeña.Info
- Publication number
- MX2008012053A MX2008012053A MX2008012053A MX2008012053A MX2008012053A MX 2008012053 A MX2008012053 A MX 2008012053A MX 2008012053 A MX2008012053 A MX 2008012053A MX 2008012053 A MX2008012053 A MX 2008012053A MX 2008012053 A MX2008012053 A MX 2008012053A
- Authority
- MX
- Mexico
- Prior art keywords
- small molecule
- compounds
- apoptosis promoters
- dimer
- molecule apoptosis
- Prior art date
Links
- 230000006907 apoptotic process Effects 0.000 title abstract 2
- 150000003384 small molecules Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 abstract 1
- 101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78461206P | 2006-03-21 | 2006-03-21 | |
| US85497506P | 2006-10-27 | 2006-10-27 | |
| PCT/US2007/064569 WO2007136921A2 (en) | 2006-03-21 | 2007-03-21 | Small molecule apoptosis promoters |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008012053A true MX2008012053A (es) | 2008-12-17 |
Family
ID=38723933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008012053A MX2008012053A (es) | 2006-03-21 | 2007-03-21 | Promotores de apoptosis de molecula pequeña. |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US7807699B2 (https=) |
| EP (1) | EP1996184A4 (https=) |
| JP (1) | JP2009530424A (https=) |
| AU (1) | AU2007254033A1 (https=) |
| BR (1) | BRPI0708942A2 (https=) |
| CA (1) | CA2646186A1 (https=) |
| MX (1) | MX2008012053A (https=) |
| WO (1) | WO2007136921A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2475207T3 (es) | 2004-07-15 | 2014-07-10 | Tetralogic Pharmaceuticals Corporation | Compuestos de unión a IAP |
| DK1836201T4 (da) | 2004-12-20 | 2013-11-11 | Genentech Inc | Pyrrolidininhibitorer af IAP. |
| MX2007010371A (es) * | 2005-02-25 | 2008-01-11 | Tetralogic Pharmaceuticals | Inhibidores dimericos iap. |
| JP4954983B2 (ja) | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | Ｂｉｒドメイン結合化合物 |
| WO2007048224A1 (en) | 2005-10-25 | 2007-05-03 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| CN101374829A (zh) | 2005-12-19 | 2009-02-25 | 健泰科生物技术公司 | Iap的抑制剂 |
| TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| US7807699B2 (en) * | 2006-03-21 | 2010-10-05 | Joyant Pharmaceuticals, Inc. | Dimeric pyrrolidine amide-containing small molecule apoptosis promoters |
| CN101535300B (zh) | 2006-05-16 | 2014-05-28 | 埃格拉医疗公司 | Iap bir域结合化合物 |
| MX2009000824A (es) | 2006-07-24 | 2009-02-04 | Tetralogic Pharmaceuticals Cor | Antagonistas dimericos de las proteinas inhibidoras de la apoptosis. |
| US20100143499A1 (en) * | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| WO2008014229A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| JP5452223B2 (ja) | 2006-07-24 | 2014-03-26 | テトラロジック ファーマシューティカルズ コーポレーション | Ｉａｐ阻害剤 |
| WO2008134679A1 (en) | 2007-04-30 | 2008-11-06 | Genentech, Inc. | Inhibitors of iap |
| JP2010528587A (ja) * | 2007-05-07 | 2010-08-26 | テトラロジック ファーマシューティカルズ コーポレーション | アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法 |
| JP2011529962A (ja) * | 2008-08-02 | 2011-12-15 | ジェネンテック， インコーポレイテッド | Ｉａｐのインヒビター |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
| US20110034469A1 (en) | 2009-08-04 | 2011-02-10 | Takeda Pharmaceutical Company Limited | Heterocyclic Compound |
| US8551955B2 (en) | 2009-10-28 | 2013-10-08 | Joyant Pharmaceuticals, Inc. | Dimeric Smac mimetics |
| CN102596321B (zh) | 2009-10-29 | 2014-11-19 | 詹森药业有限公司 | 可用作dpp-1抑制剂的炔基衍生物 |
| US9284350B2 (en) | 2010-02-12 | 2016-03-15 | Pharmascience Inc. | IAP BIR domain binding compounds |
| UY33236A (es) | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
| UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
| JP5906253B2 (ja) * | 2010-12-16 | 2016-04-20 | アッヴィ・インコーポレイテッド | 抗ウイルス性化合物 |
| US20140163229A1 (en) * | 2011-04-07 | 2014-06-12 | Cornell University | Silyl monomers capable of multimerizing in an aqueous solution, and methods of using same |
| US9453048B2 (en) * | 2012-08-09 | 2016-09-27 | Bristol-Myers Squibb Company | IAP antagonists |
| PL405505A1 (pl) * | 2013-09-30 | 2015-04-13 | Warszawski Uniwersytet Medyczny | Zastosowanie pochodnej kwasu diaminodikarboksylowego jako inhibitora aktywności biologicznej IL-15 I IL-2 |
| RU2685505C1 (ru) * | 2018-11-29 | 2019-04-19 | Михаил Владимирович Овчинников | Гетероциклические амиды тирозина, обладающие анальгетическим, противовоспалительным и противоотечным действием |
| CN113677399B (zh) * | 2019-04-05 | 2024-10-11 | 和博医药有限公司 | 凋亡蛋白抑制剂的二价拮抗剂 |
| WO2021148396A1 (en) | 2020-01-20 | 2021-07-29 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| AU2022239717A1 (en) | 2021-03-15 | 2023-11-02 | Maze Therapeutics, Inc. | Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1495124A2 (en) | 2002-04-17 | 2005-01-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Smac-peptides as therapeutics against cancer and autoimmune diseases |
| WO2005084317A2 (en) * | 2004-03-01 | 2005-09-15 | Board Of Regents, The University Of Texas System | Dimeric small molecule potentiators of apoptosis |
| ES2475207T3 (es) | 2004-07-15 | 2014-07-10 | Tetralogic Pharmaceuticals Corporation | Compuestos de unión a IAP |
| WO2007048224A1 (en) * | 2005-10-25 | 2007-05-03 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| TWI504597B (zh) * | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| US7807699B2 (en) * | 2006-03-21 | 2010-10-05 | Joyant Pharmaceuticals, Inc. | Dimeric pyrrolidine amide-containing small molecule apoptosis promoters |
-
2007
- 2007-03-21 US US11/726,602 patent/US7807699B2/en not_active Expired - Fee Related
- 2007-03-21 WO PCT/US2007/064569 patent/WO2007136921A2/en not_active Ceased
- 2007-03-21 BR BRPI0708942-2A patent/BRPI0708942A2/pt not_active IP Right Cessation
- 2007-03-21 MX MX2008012053A patent/MX2008012053A/es unknown
- 2007-03-21 CA CA002646186A patent/CA2646186A1/en not_active Abandoned
- 2007-03-21 AU AU2007254033A patent/AU2007254033A1/en not_active Abandoned
- 2007-03-21 EP EP07759058A patent/EP1996184A4/en not_active Withdrawn
- 2007-03-21 JP JP2009509903A patent/JP2009530424A/ja not_active Withdrawn
-
2010
- 2010-10-04 US US12/897,760 patent/US8222291B2/en not_active Expired - Fee Related
-
2012
- 2012-06-28 US US13/536,974 patent/US8586542B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1996184A2 (en) | 2008-12-03 |
| US20120082640A1 (en) | 2012-04-05 |
| JP2009530424A (ja) | 2009-08-27 |
| US8222291B2 (en) | 2012-07-17 |
| BRPI0708942A2 (pt) | 2011-06-14 |
| WO2007136921A3 (en) | 2008-03-20 |
| CA2646186A1 (en) | 2007-11-29 |
| EP1996184A4 (en) | 2010-09-22 |
| AU2007254033A1 (en) | 2007-11-29 |
| US8586542B2 (en) | 2013-11-19 |
| US20130281385A1 (en) | 2013-10-24 |
| WO2007136921A2 (en) | 2007-11-29 |
| US20080051389A1 (en) | 2008-02-28 |
| US7807699B2 (en) | 2010-10-05 |
| WO2007136921A8 (en) | 2008-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2008012053A (es) | Promotores de apoptosis de molecula pequeña. | |
| MX2009010667A (es) | Dimeros y trimeros mimeticos de smac utiles como agentes anti-cancer. | |
| EP2493879A4 (en) | DIMERE SMAC MIMETIKA | |
| MX2009008104A (es) | Hepcidina, antagonistas de hepcidina y metodos de uso. | |
| NO20092470L (no) | Substituerte diazepanforbindelser som orexinreseptorantagonister | |
| EA201170624A1 (ru) | Изоникотинамидные антагонисты рецепторов орексинов | |
| EA201170155A1 (ru) | Специфические антагонисты рецептора fgf-r4 | |
| DK2049529T3 (da) | Substituerede diazepan-orexin-receptor- antagonister | |
| EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
| GT200800198A (es) | Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide del tipo 1. | |
| MX2014005411A (es) | Construcciones prolongadas de la vida media de la proteina relacionada con lipoproteina de baja densidad 6 (lrp6). | |
| MX2009006339A (es) | Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide. | |
| EA201390666A1 (ru) | Cxcr2-связывающие полипептиды | |
| UA99620C2 (en) | Pyridyl piperidine orexin receptor antagonists | |
| IL197080A0 (en) | Pyrimidone compounds as gsk-3 inhibitors | |
| UA100974C2 (ru) | Соединения замещенных диазепанов как антагонисты орексиновых рецепторов | |
| MX2012006206A (es) | Preparaciones combinacion comprendiendo exosomas y corticosteroide. | |
| EA201171074A1 (ru) | Цитотоксические конъюгаты с соединением, связывающим рецептор нейропептида y | |
| WO2015063747A3 (en) | Peptide inhibitors of tead/yap-taz interaction | |
| NO20084006L (no) | Modulatorer av muskarinreseptorer | |
| MX2009004757A (es) | Moduladores de regeneracion neuronal. | |
| WO2011116212A3 (en) | Bone morphogenetic protein receptor binding agents and methods of their use | |
| ATE472998T1 (de) | Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis | |
| WO2011022393A3 (en) | Phosphatidylcholine transfer protein inhibitors | |
| ATE474574T1 (de) | Imidazoazephinonverbindungen |